Cargando…

Evaluation of serum levels of Irisin as a marker of endothelial dysfunction in patients with type 2 diabetes mellitus

INTRODUCTION: Insulin resistance and obesity have been associated with irisin, a protein in fat cells. The levels of irisin in patients with type 2 diabetes mellitus (T2DM) were significantly lower than those in non‐diabetics. This study aimed to examine the relationship between serum irisin levels...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Thoraya Mohamed, Nassar, Mahmoud, Mohamed, Hanaa Ahmed Abdallah, Elhadidy, Khaled El‐sayed, Farhan, Hanan Mohamed, El Basset, Ahmed Sayed Abd, Elmessiery, Riem M., Kamel, Mahmoud Farid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164434/
https://www.ncbi.nlm.nih.gov/pubmed/36919265
http://dx.doi.org/10.1002/edm2.403
_version_ 1785038067863650304
author Ahmed, Thoraya Mohamed
Nassar, Mahmoud
Mohamed, Hanaa Ahmed Abdallah
Elhadidy, Khaled El‐sayed
Farhan, Hanan Mohamed
El Basset, Ahmed Sayed Abd
Elmessiery, Riem M.
Kamel, Mahmoud Farid
author_facet Ahmed, Thoraya Mohamed
Nassar, Mahmoud
Mohamed, Hanaa Ahmed Abdallah
Elhadidy, Khaled El‐sayed
Farhan, Hanan Mohamed
El Basset, Ahmed Sayed Abd
Elmessiery, Riem M.
Kamel, Mahmoud Farid
author_sort Ahmed, Thoraya Mohamed
collection PubMed
description INTRODUCTION: Insulin resistance and obesity have been associated with irisin, a protein in fat cells. The levels of irisin in patients with type 2 diabetes mellitus (T2DM) were significantly lower than those in non‐diabetics. This study aimed to examine the relationship between serum irisin levels and endothelial dysfunction in patients with T2DM. METHODS: There were 90 participants in this study. We matched 65 patients with T2DM with 25 healthy control participants. A series of tests were performed on the participants, including fasting blood glucose, 2 hours postprandial blood glucose, glycated haemoglobin, triglycerides (TG), total cholesterol, high‐density lipoprotein cholesterol (HDL‐C), low‐density lipoprotein cholesterol (LDL‐C), TG/HDL‐C ratio and albumin/creatinine ratio. In addition to measuring high‐sensitivity C‐reactive protein (hs‐CRP). Enzyme‐linked immunosorbent assay (ELISA) technique was used for estimating irisin concentrations. RESULTS: Flow‐mediated dilation (FMD) was significantly lower in patients with T2DM; however, there was a non‐statistically significant difference between healthy controls and patients with T2DM regarding serum Irisin level. CRP and LDL levels were inversely correlated with circulating irisin levels. In a stepwise regression analysis, only the hs‐CRP and LDL were statistically significant in predicting irisin level. CONCLUSIONS: In patients with T2DM, serum levels of irisin were inversely correlated with hyperglycaemia, body mass index and per cent body fat; this suggests that detecting irisin levels early can prevent cardiovascular diseases from progressing. According to the study results, serum irisin serves as a predictive marker for early cardiovascular disease, thus preventing the disease from progressing. There is a need for further research in order to understand how irisin contributes to the development of atherosclerosis and the development of diabetic complications.
format Online
Article
Text
id pubmed-10164434
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101644342023-05-08 Evaluation of serum levels of Irisin as a marker of endothelial dysfunction in patients with type 2 diabetes mellitus Ahmed, Thoraya Mohamed Nassar, Mahmoud Mohamed, Hanaa Ahmed Abdallah Elhadidy, Khaled El‐sayed Farhan, Hanan Mohamed El Basset, Ahmed Sayed Abd Elmessiery, Riem M. Kamel, Mahmoud Farid Endocrinol Diabetes Metab Research Articles INTRODUCTION: Insulin resistance and obesity have been associated with irisin, a protein in fat cells. The levels of irisin in patients with type 2 diabetes mellitus (T2DM) were significantly lower than those in non‐diabetics. This study aimed to examine the relationship between serum irisin levels and endothelial dysfunction in patients with T2DM. METHODS: There were 90 participants in this study. We matched 65 patients with T2DM with 25 healthy control participants. A series of tests were performed on the participants, including fasting blood glucose, 2 hours postprandial blood glucose, glycated haemoglobin, triglycerides (TG), total cholesterol, high‐density lipoprotein cholesterol (HDL‐C), low‐density lipoprotein cholesterol (LDL‐C), TG/HDL‐C ratio and albumin/creatinine ratio. In addition to measuring high‐sensitivity C‐reactive protein (hs‐CRP). Enzyme‐linked immunosorbent assay (ELISA) technique was used for estimating irisin concentrations. RESULTS: Flow‐mediated dilation (FMD) was significantly lower in patients with T2DM; however, there was a non‐statistically significant difference between healthy controls and patients with T2DM regarding serum Irisin level. CRP and LDL levels were inversely correlated with circulating irisin levels. In a stepwise regression analysis, only the hs‐CRP and LDL were statistically significant in predicting irisin level. CONCLUSIONS: In patients with T2DM, serum levels of irisin were inversely correlated with hyperglycaemia, body mass index and per cent body fat; this suggests that detecting irisin levels early can prevent cardiovascular diseases from progressing. According to the study results, serum irisin serves as a predictive marker for early cardiovascular disease, thus preventing the disease from progressing. There is a need for further research in order to understand how irisin contributes to the development of atherosclerosis and the development of diabetic complications. John Wiley and Sons Inc. 2023-03-14 /pmc/articles/PMC10164434/ /pubmed/36919265 http://dx.doi.org/10.1002/edm2.403 Text en © 2023 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Ahmed, Thoraya Mohamed
Nassar, Mahmoud
Mohamed, Hanaa Ahmed Abdallah
Elhadidy, Khaled El‐sayed
Farhan, Hanan Mohamed
El Basset, Ahmed Sayed Abd
Elmessiery, Riem M.
Kamel, Mahmoud Farid
Evaluation of serum levels of Irisin as a marker of endothelial dysfunction in patients with type 2 diabetes mellitus
title Evaluation of serum levels of Irisin as a marker of endothelial dysfunction in patients with type 2 diabetes mellitus
title_full Evaluation of serum levels of Irisin as a marker of endothelial dysfunction in patients with type 2 diabetes mellitus
title_fullStr Evaluation of serum levels of Irisin as a marker of endothelial dysfunction in patients with type 2 diabetes mellitus
title_full_unstemmed Evaluation of serum levels of Irisin as a marker of endothelial dysfunction in patients with type 2 diabetes mellitus
title_short Evaluation of serum levels of Irisin as a marker of endothelial dysfunction in patients with type 2 diabetes mellitus
title_sort evaluation of serum levels of irisin as a marker of endothelial dysfunction in patients with type 2 diabetes mellitus
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164434/
https://www.ncbi.nlm.nih.gov/pubmed/36919265
http://dx.doi.org/10.1002/edm2.403
work_keys_str_mv AT ahmedthorayamohamed evaluationofserumlevelsofirisinasamarkerofendothelialdysfunctioninpatientswithtype2diabetesmellitus
AT nassarmahmoud evaluationofserumlevelsofirisinasamarkerofendothelialdysfunctioninpatientswithtype2diabetesmellitus
AT mohamedhanaaahmedabdallah evaluationofserumlevelsofirisinasamarkerofendothelialdysfunctioninpatientswithtype2diabetesmellitus
AT elhadidykhaledelsayed evaluationofserumlevelsofirisinasamarkerofendothelialdysfunctioninpatientswithtype2diabetesmellitus
AT farhanhananmohamed evaluationofserumlevelsofirisinasamarkerofendothelialdysfunctioninpatientswithtype2diabetesmellitus
AT elbassetahmedsayedabd evaluationofserumlevelsofirisinasamarkerofendothelialdysfunctioninpatientswithtype2diabetesmellitus
AT elmessieryriemm evaluationofserumlevelsofirisinasamarkerofendothelialdysfunctioninpatientswithtype2diabetesmellitus
AT kamelmahmoudfarid evaluationofserumlevelsofirisinasamarkerofendothelialdysfunctioninpatientswithtype2diabetesmellitus